Phase I/II study of human chorionic gonadotropin and epidermal growth factor supplementation (Pregnyl®) to support tolerance and repair as adjunct therapy in high-risk or refractory acute graft-versus-host disease
Research Grant Recipient: Shernan Holtan, MD
Grant Period: 2017-2019
Award Value: $497,966
Site: University of Minnesota
Interim report: Patient enrollment continues. Additionally, correlative studies have provided important data on regulatory T cell responses and other markers that give insight to the clinical trial and help strengthen the results.
This grant is in no-cost extension through 2/28/2020.
Summary: After a bone marrow transplant, patients sometimes suffer a severe complication called graft-versus-host disease (GVHD), where the donor immune cells attack the patient's organs and tissues. Dr. Holtan is testing the safety and effectiveness of using high concentrations of growth hormones to help patients with GVHD recover from the damage better and faster.
Shernan Holtan, MD, is an Assistant Professor of Medicine in the Division of Hematology, Oncology, and Transplantation at the University of Minnesota. Dr. Holton is a member of the CIBMTR Late Effects, Immunobiology, and GVHD working committees. She received the OHSU Red Rose Award in 2013 and the Edward T. Creagan Award for Outstanding Contribution to Melanoma Research in 2011.